Ads
related to: myeloma cancerfreshdiscover.com has been visited by 100K+ users in the past month
alternativebee.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]
Smouldering myeloma is a disease classified as intermediate in a spectrum of step-wise progressive diseases termed plasma cell dyscrasias. In this spectrum of diseases, a clone of plasma cells secreting monoclonal paraprotein (also termed myeloma protein or M protein) causes the relatively benign disease of monoclonal gammopathy of undetermined ...
Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within the axial skeleton.. The International Myeloma Working Group lists three types: solitary plasmacytoma of bone (SPB); extramedullary plasmacytoma (EP), and multiple plasmacytomas that are either primary or recurrent. [1]
Multiple myeloma is a rare blood cancer affecting the body's plasma cells, which are white blood cells mainly found in bone marrow that make antibodies to fight infection.
The International Myeloma Foundation (IMF) is an American non-profit organization serving patients with myeloma, a cancer of plasma cells in the bone marrow.The IMF also provides support and information for family members, caregivers of myeloma patients, physicians and nurses.
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, [5] a type of white blood cell cancer, [6] in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count.
Ads
related to: myeloma cancerfreshdiscover.com has been visited by 100K+ users in the past month
alternativebee.com has been visited by 10K+ users in the past month